IDN-6556 is a lead compound from a class of small-molecule caspase protease inhibitors, and is currently under development by Idun as a potential treatment for acute alcoholic and infectious hepatitis. In October 2003, a phase II trial of IDN-6556 began in 100 patients undergoing liver transplantation.
|Original language||English (US)|
|Number of pages||7|
|Journal||Current Opinion in Investigational Drugs|
|State||Published - Nov 1 2004|
ASJC Scopus subject areas
- Drug Discovery